Last edition
News about Global Pharma
Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. These genetic data have been paired with detailed health information to create this browsable resource
Global Pharma | 10/07/2021 | By Darshana | 176
Sinomed, a leading international medical device company, announced that they have teamed up with the National University of Ireland Galway (NUI Galway) to conduct a clinical trial for a new assessment method for stenting
Global Pharma | 06/07/2021 | By Darshana | 208
Moderna begins manufacturing of Covid-19 vaccine at Recipharm site in France
Moderna Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines; and Recipharm, a leading contract development and manufacturing organization, confirmed that following the European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) approval of the Recipharm Monts site on June 11, 2021, drug product manufacture
Global Pharma | 03/07/2021 | By Darshana | 259
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced a new agreement to commercialize the Moderna Covid-19 vaccine across Central Eastern Europe and Israel
Global Pharma | 08/06/2021 | By Darshana | 241
Bayer enters agreement to buy Noria Therapeutics and PSMA Therapeutics
Bayer announced that it has entered into an agreement to acquire Noria Therapeutics (Noria) and PSMA Therapeutics. Through this acquisition, Bayer will obtain exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA)
Global Pharma | 06/06/2021 | By Darshana | 295
Bharat Biotech signs agreement with Ocugen to commercialise Covaxin in Canada
Ocugen, Inc., a biopharmaceutical company, and Bharat Biotech, a global leader in vaccine innovation, announced that they have entered into an amendment to their co-development, supply, and commercialization agreement to expand Ocugen's exclusive territory to commercialize Covaxin to now also include Canada
Global Pharma | 04/06/2021 | By Darshana | 198
Bayer launches consumer health division in India
Bayer, a global life sciences company, now announces the launch of its consumer health division in India. Globally, Bayer's Consumer Health division encompasses over 140 brands. The newly launched consumer health business in India comprises of 10 trusted consumer health brands across the categories of allergy, dermatology, nutrition and analgesics
Global Pharma | 04/06/2021 | By Darshana | 436
WHO validates Sinovac-CoronaVac Covid-19 vaccine for emergency use
WHO validated the Sinovac-CoronaVac Covid-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac
Global Pharma | 03/06/2021 | By Darshana | 207
Biohaven's Nurtec ODT receives US FDA approval for preventive treatment of migraine
Biohaven Pharmaceutical Holding Company Ltd, a biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine
Global Pharma | 30/05/2021 | By Darshana | 505
The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a phase 2 study with 722 volunteers. A global pivotal phase 3 study is expected to start in the coming weeks
Global Pharma | 18/05/2021 | By Darshana | 180
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy